These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 1888834)

  • 21. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis.
    Eriksson S; Långström G; Rikner L; Carlsson R; Naesdal J
    Eur J Gastroenterol Hepatol; 1995 May; 7(5):467-75. PubMed ID: 7614110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abdominal pain in hereditary angioedema: the role of acid hypersecretion.
    Collen MJ; Brickman CM; Lewis JH; Deschner WK; Ansher AF; Zurlo JJ; Benjamin SB; Frank MM
    Am J Gastroenterol; 1989 Aug; 84(8):873-7. PubMed ID: 2756979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
    Barradell LB; Faulds D; McTavish D
    Drugs; 1992 Aug; 44(2):225-50. PubMed ID: 1382017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bleeding duodenal ulcer. Role of gastric acid hypersecretion.
    Collen MJ; Kalloo AN; Sheridan MJ
    Dig Dis Sci; 1993 Feb; 38(2):269-75. PubMed ID: 8093870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
    Langtry HD; Wilde MI
    Drugs; 1997 Sep; 54(3):473-500. PubMed ID: 9279507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time of administration influences gastric inhibitory effects of ranitidine.
    Johnston DA; Wormsley KG
    Scand J Gastroenterol; 1988 Nov; 23(9):1137-40. PubMed ID: 3247592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger-Ellison syndrome.
    Termanini B; Gibril F; Stewart CA; Weber HC; Jensen RT
    Aliment Pharmacol Ther; 1996 Feb; 10(1):61-71. PubMed ID: 8871445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gastric acid secretion and plasma gastrin during short-term treatment with omeprazole and ranitidine in duodenal ulcer patients.
    Lazzaroni M; Sangaletti O; Bianchi Porro G
    Hepatogastroenterology; 1992 Aug; 39(4):366-70. PubMed ID: 1427586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gastro-oesophageal reflux during 3 months of therapy with ranitidine in reflux oesophagitis.
    Hatlebakk JG; Berstad A
    Scand J Gastroenterol; 1996 Oct; 31(10):954-8. PubMed ID: 8898414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of H2-receptor blockade by ranitidine on ulcer healing and gastric acid secretion in patients with gastric and duodenal ulcers.
    Forssell H; Koch G
    Eur J Clin Pharmacol; 1983; 25(2):195-8. PubMed ID: 6313376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial.
    Bardhan KD; Naesdal J; Bianchi Porro G; Petrillo M; Lazzaroni M; Hinchliffe RF; Thompson M; Morris P; Daly MJ; Carroll NJ
    Gut; 1991 Apr; 32(4):435-8. PubMed ID: 1673953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome.
    Pisegna JR; Norton JA; Slimak GG; Metz DC; Maton PN; Gardner JD; Jensen RT
    Gastroenterology; 1992 Mar; 102(3):767-78. PubMed ID: 1537514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine.
    Richards DA
    J Clin Gastroenterol; 1983; 5 Suppl 1():81-90. PubMed ID: 6317740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
    Cheer SM; Prakash A; Faulds D; Lamb HM
    Drugs; 2003; 63(1):101-33. PubMed ID: 12487624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medical therapy of peptic ulcer disease.
    McQuaid KR; Isenberg JI
    Surg Clin North Am; 1992 Apr; 72(2):285-316. PubMed ID: 1347960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease.
    Howden CW; Burget DW; Hunt RH
    Scand J Gastroenterol Suppl; 1994; 201():79-82. PubMed ID: 8047830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparative study of cisapride and ranitidine at controlling oesophageal acid exposure in erosive oesophagitis.
    Pouderoux P; Kahrilas PJ
    Aliment Pharmacol Ther; 1995 Dec; 9(6):661-6. PubMed ID: 8824654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Helicobacter pylori in duodenal ulcer patients with idiopathic gastric acid hypersecretion.
    Collen MJ; Strong RM
    Dig Dis Sci; 1993 Jan; 38(1):132-6. PubMed ID: 8420745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Omeprazole in the management of refractory duodenal ulcer.
    Bardhan KD
    Scand J Gastroenterol Suppl; 1989; 166():63-73. PubMed ID: 2574910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Appropriate acid suppression in the treatment of acid-related conditions.
    Howden CW
    Pharmacol Ther; 1994; 63(1):123-34. PubMed ID: 7972343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.